PRLD - Prelude Therapeutics Incorporated
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$8.00
DETAILS
HIGH:
$8.00
LOW:
$8.00
MEDIAN:
$8.00
CONSENSUS:
$8.00
UPSIDE:
72.41%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| Revenue | 12.1 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 |
| Gross Profit | 10.4 | 7 | 0 | 0 | 0 | 0 | 0 | (0.1) |
| Operating Expenses | ||||||||
| R&D Expenses | 94.3 | 118.0 | 103.4 | 92.9 | 86.8 | 48.2 | 24.3 | 12.6 |
| SG&A Expenses | 22.4 | 28.7 | 28.9 | 30.7 | 27.0 | 10.6 | 3.8 | 2.4 |
| Other Expenses | (1.7) | 0 | (0.0) | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 115.0 | 146.7 | 132.3 | 123.5 | 113.7 | 58.8 | 28.1 | 15.0 |
| Operating Income | ||||||||
| Operating Income | (104.6) | (139.7) | (132.3) | (123.5) | (113.7) | (58.8) | (28.1) | (15.0) |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profitability | ||||||||
| EBITDA | (97.8) | (125.4) | (120.7) | (114.1) | (110.8) | (58.2) | (27.7) | (14.8) |
| EBIT | (99.5) | (127.2) | (121.8) | (115.4) | (111.7) | (58.8) | (28.1) | (15.0) |
| Income Before Tax | (99.5) | (127.2) | (121.8) | (115.4) | (111.7) | (56.9) | (27.6) | (14.7) |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (99.5) | (127.2) | (121.8) | (115.4) | (111.7) | (56.9) | (27.6) | (14.7) |
| Per Share Data | ||||||||
| EPS (Basic) | -1.29 | -1.68 | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -9.31 |
| EPS (Diluted) | -1.29 | -1.68 | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -9.31 |
| Shares Outstanding | 77.0 | 75.8 | 60.4 | 47.4 | 47.6 | 43.7 | 32.4 | 1.6 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||
| Cash & Cash Equivalents | 35.3 | 12.5 | 25.3 | 30.6 | 31.8 | 218.3 | 18.9 | 15.6 |
| Short-Term Investments | 68.0 | 121.1 | 207.6 | 171.1 | 259.4 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.5 | 2.3 | 2.7 | 2.7 | 0 | 2.5 | 0 | 0 |
| Total Current Assets | 105.7 | 135.9 | 235.6 | 204.4 | 295.1 | 220.8 | 20.2 | 15.6 |
| Non-Current Assets | ||||||||
| Property, Plant & Equipment | 32.3 | 35.5 | 37.7 | 6.7 | 5.6 | 2.5 | 1.6 | 0.8 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 3.3 | 4.2 | 4.3 | 9.4 | 4.3 | 0.3 | 0 | 0 |
| Total Non-Current Assets | 35.6 | 39.6 | 42.1 | 16.1 | 10.0 | 2.8 | 1.6 | 0.8 |
| Total Assets | 141.3 | 175.5 | 277.7 | 220.5 | 305.1 | 223.6 | 21.9 | 16.4 |
| Current Liabilities | ||||||||
| Account Payables | 4.0 | 7.7 | 4.6 | 6.8 | 7.8 | 3.9 | 2.0 | 1.4 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 33.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.4 | 9.8 | 6.6 | 6.2 | 5.0 | 0.4 | 1.6 | 0 |
| Total Current Liabilities | 53.0 | 25.6 | 21.8 | 21.7 | 19.2 | 11.4 | 4.8 | 2.4 |
| Non-Current Liabilities | ||||||||
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.8 | 3.1 | 3.3 | 3.4 | 0 | 0.0 | 66.4 | 36.7 |
| Total Non-Current Liabilities | 19.7 | 18.4 | 18.7 | 3.4 | 0 | 0.0 | 66.4 | 36.7 |
| Total Liabilities | 72.7 | 44.1 | 40.6 | 25.1 | 19.2 | 11.4 | 71.3 | 39.1 |
| Stockholders' Equity | ||||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 |
| Retained Earnings | (683.1) | (583.6) | (456.4) | (334.6) | (219.1) | (107.4) | (50.5) | (22.9) |
| Accumulated Other Comprehensive Income | 0.0 | 0.0 | 0.2 | (1.7) | (0.7) | (223.6) | 0 | (0.2) |
| Total Stockholders' Equity | 68.6 | 131.5 | 237.1 | 195.4 | 285.9 | 212.2 | (49.4) | (22.7) |
| Total Liabilities & Equity | 141.3 | 175.5 | 277.7 | 220.5 | 305.1 | 223.6 | 21.9 | 16.4 |
| Debt Metrics | ||||||||
| Total Debt | 17.8 | 18.0 | 16.9 | 1.8 | 1.7 | 0 | 0.3 | 0 |
| Net Debt | (17.5) | 5.6 | (8.4) | (28.8) | (30.1) | (218.3) | (18.6) | (15.6) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | (99.5) | (127.2) | (121.8) | (115.4) | (111.7) | (56.9) | (27.6) | (14.7) |
| Depreciation & Amortization | 1.3 | 1.8 | 1.2 | 1.3 | 0.9 | 0.5 | 0.4 | 0.1 |
| Stock-Based Compensation | 11.9 | 21.3 | 25.6 | 25.1 | 20.9 | 5.6 | 0.8 | 0.2 |
| Change in Working Capital | 28.4 | 4.2 | (10.5) | 0.9 | 3.6 | 4.6 | 0.7 | 1.4 |
| Other Non-Cash Items | 1.5 | (3.0) | (1.5) | 4.3 | 2.7 | 0.0 | 0.0 | 0.0 |
| Operating Cash Flow | (56.3) | (102.9) | (107.1) | (83.7) | (83.5) | (46.2) | (25.7) | (13.0) |
| Investing Activities | ||||||||
| Capital Expenditure | (0.1) | (0.8) | (3.5) | (3.0) | (2.3) | (0.6) | (0.8) | (0.5) |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (100.9) | (52.7) | (221.6) | (119.2) | (261.5) | 0 | 0 | 0 |
| Sales/Maturities of Investments | 154.4 | 143.6 | 190.5 | 203.9 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 53.5 | 90.2 | (34.6) | 81.7 | (263.8) | (0.6) | (0.8) | (0.5) |
| Financing Activities | ||||||||
| Net Debt Issuance | (0.2) | (0.4) | 0 | 0 | 0 | (0.3) | (0.1) | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.0) | (0.1) | 0.7 | 0 | 3.5 | 0.1 | 0.0 | 0 |
| Financing Cash Flow | 24.8 | (0.1) | 136.4 | 0.8 | 164.9 | 246.2 | 29.7 | 17.9 |
| Cash Position | ||||||||
| Net Change in Cash | 22.0 | (12.8) | (5.3) | (1.2) | (182.4) | 199.4 | 3.3 | 4.5 |
| Cash at Beginning | 16.5 | 29.3 | 34.6 | 35.9 | 218.3 | 18.9 | 15.6 | 11.1 |
| Cash at End | 38.5 | 16.5 | 29.3 | 34.6 | 35.9 | 218.3 | 18.9 | 15.6 |
| Free Cash Flow | (56.4) | (103.7) | (110.6) | (86.7) | (85.9) | (46.8) | (26.4) | (13.5) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 12.1 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 10.4 | 7 | 0 | 0 | 0 | 0 | 0 | (0.1) |
| Operating Income | (104.6) | (139.7) | (132.3) | (123.5) | (113.7) | (58.8) | (28.1) | (15.0) |
| Net Income | (99.5) | (127.2) | (121.8) | (115.4) | (111.7) | (56.9) | (27.6) | (14.7) |
| EPS (Diluted) | -1.29 | -1.68 | -2.02 | -2.27 | -2.33 | -1.30 | -0.85 | -9.31 |
| Balance Sheet | ||||||||
| Cash & Equivalents | 35.3 | 12.5 | 25.3 | 30.6 | 31.8 | 218.3 | 18.9 | 15.6 |
| Total Assets | 141.3 | 175.5 | 277.7 | 220.5 | 305.1 | 223.6 | 21.9 | 16.4 |
| Total Debt | 17.8 | 18.0 | 16.9 | 1.8 | 1.7 | 0 | 0.3 | 0 |
| Stockholders' Equity | 68.6 | 131.5 | 237.1 | 195.4 | 285.9 | 212.2 | (49.4) | (22.7) |
| Cash Flow | ||||||||
| Operating Cash Flow | (56.3) | (102.9) | (107.1) | (83.7) | (83.5) | (46.2) | (25.7) | (13.0) |
| Capital Expenditure | (0.1) | (0.8) | (3.5) | (3.0) | (2.3) | (0.6) | (0.8) | (0.5) |
| Free Cash Flow | (56.4) | (103.7) | (110.6) | (86.7) | (85.9) | (46.8) | (26.4) | (13.5) |